Weight-Loss Treatments Reduce UK Household Grocery Spending in New Study

Victor Chen | AA

UK households using GLP-1 weight-loss medications cut grocery spending by millions as behavior shifts, with major implications for retail and urban health policies.

A new study has revealed how the increasing adoption of GLP-1 weight-loss treatments is reshaping food purchasing habits in the UK. Conducted by Worldpanel by Numerator, the survey covered over 11,600 households, finding that use of these medications has nearly tripled in two years. Currently, 1.9 million adults in Great Britain are estimated to be using GLP-1 drugs, including Mounjaro and Wegovy.

The analysis shows that households with at least one user of GLP-1 treatments spent £780 million less on groceries than comparable households without users. This represents a decrease of £418 in yearly grocery costs per GLP-1-user household. Additionally, 299 million fewer grocery items were purchased during February, reflecting behavioral shifts tied to the medications’ appetite-suppressing effects.

Impact on Eating Habits

The study highlights profound changes in eating behaviors. Over half of GLP-1 users surveyed described their approach to food as 'mindful,' characterized by eating based on hunger rather than habit or routine. Additionally, 54% indicated fewer cravings and reduced 'food noise,' while 11% reported losing interest in their favorite foods and drinks. These shifts are directly linked to GLP-1’s appetite-regulating properties, which are changing how individuals interact with food and grocery markets.

Implications for Urban Retail and Public Health

For urban leaders and policymakers, the rising use of GLP-1 treatments carries complex implications for cities. With reduced grocery spending, supermarket chains and local food retailers in dense areas may face shifting demand patterns, prompting adjustments to inventory and pricing strategies. Public health departments may see new opportunities to integrate these treatments into obesity reduction efforts, but careful monitoring is necessary to ensure equitable access and address potential socioeconomic disparities.

Cities will also need to balance private sector impacts with possible benefits to residents' health and quality of life. Local governments may explore partnerships between health agencies and retailers to promote healthier food options in light of changing consumption habits. Urban planning professionals could use this data to refine community programs aimed at tackling obesity-related issues over the long term.

Questions That Matter

How are GLP-1 drugs affecting grocery spending?

GLP-1 medications have led to a reduction of £780 million in grocery spending by UK households with users, according to a survey of over 11,600 households.

What percentage of UK households use GLP-1 treatments?

As of 2026, 6.3% of UK households include at least one GLP-1 user, up from 4.1% in 2025 and 2.3% in 2024.